Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02321631
Other study ID # REC 57-073-13-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date March 2018

Study information

Verified date March 2020
Source Prince of Songkla University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to study the effects of EPA-enriched supplement compared with conventional supplement in malnourished head and neck cancer patients undergone surgery. Primary outcome is perioperative weight changing.


Description:

To study the effects of EPA-enriched supplement compared with conventional supplement in malnourished head and neck cancer patients undergone surgery. The patients are divided into 2 groups receiving the different formula supplements. The both supplements are isocaloric. The patients receive the supplement for 3 weeks (1 week prior to surgery and 2 weeks post surgery) Primary outcome is perioperative weight changing. Secondary outcomes are body compositions, hospital stay days, complication and co-morbidity.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 15 Years to 90 Years
Eligibility Inclusion Criteria:

1. Patients diagnosed as Head an Neck cancer with pathological confirmation

2. Receiving surgery as a primary treatment

3. Malnutrition screening tool(MST) is 2 or more

Exclusion Criteria:

1. Previously irradiated patient in the Head and Neck region

2. Previously receiving chemotherapy

3. Renal insufficiency with serum creatinine > 2.5 mg/dL

4. Liver function abnormality with total serum bilirubin > 3.0 mg/dL

5. Pregnancy

Study Design


Intervention

Dietary Supplement:
EPA-enriched supplement
EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
standard formula supplement
The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.

Locations

Country Name City State
Thailand Prince of Songkla University Hatyai Songkhla

Sponsors (1)

Lead Sponsor Collaborator
Prince of Songkla University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Body weight at 3 weeks Body weight measured in kilogram 3 weeks
Primary Change from baseline in Body weight at 1 month Body weight measured in kilogram 1 month
Primary Change from baseline in Body weight at 3 months Body weight measured in kilogram 3 months
Secondary Change from baseline in fat-free mass percentage at 3 weeks Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) 3 weeks
Secondary Change from baseline in fat-free mass percentage at 1 month Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) 1 month
Secondary Change from baseline in fat-free mass percentage at 3 months Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) 3 months
Secondary Change from baseline in body fat percentage at 3 weeks Percent of body fat on the Bioelectrical Impedance Analysis (BIA) 3 weeks
Secondary Change from baseline in body fat percentage at 1 month Percent of body fat on the Bioelectrical Impedance Analysis (BIA) 1 month
Secondary Change from baseline in body fat percentage at 3 months Percent of body fat on the Bioelectrical Impedance Analysis (BIA) 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2